{
    "clinical_study": {
        "@rank": "141099", 
        "arm_group": [
            {
                "arm_group_label": "Lipid 1", 
                "arm_group_type": "Active Comparator", 
                "description": "Meal intake"
            }, 
            {
                "arm_group_label": "Lipid-free", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Maltodextrine + proteins"
            }, 
            {
                "arm_group_label": "Lipid 2", 
                "arm_group_type": "Active Comparator", 
                "description": "Meal intake"
            }, 
            {
                "arm_group_label": "Lipid 3", 
                "arm_group_type": "Active Comparator", 
                "description": "Meal intake"
            }, 
            {
                "arm_group_label": "Lipid 4", 
                "arm_group_type": "Active Comparator", 
                "description": "meal intake"
            }
        ], 
        "brief_summary": {
            "textblock": "This pilot study is aimed at assessing the acute effect of several combinations of lipids\n      differing in their fatty acid composition on glucagon-like-peptide (GLP)-2 and GLP-1\n      secretion in healthy subjects."
        }, 
        "brief_title": "Boosting the Secretion of GLP-2 and GLP-1 Intestinal Hormones by Nutrients", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "In this study, the investigators aim to investigate the effect of various lipid types on\n      GLP-2 and GLP-1 secretion. This will allow to determine the importance of lipids in\n      nutritional solutions. Moreover, this will allow us to assess whether existing clinical\n      formulas can be improved in order to stimulate GLP-2 and accelerate intestinal recovery."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  BMI : 19 - 24.9 kg.m-2\n\n          -  Normal fasting glycemia\n\n          -  Having obtained his informed consent.\n\n        Exclusion Criteria:\n\n          -  Gastro-intestinal disease (ulcer), pancreatic disease, hepatic disease, metabolic\n             diseases / disorders (diabetes, dyslipidemia), renal disease, cardiovascular disease\n             (arterial hypertension), as determined by the medical screening visit and a blood\n             analysis.\n\n          -  Have had a gastrointestinal surgery (with the exception of appendices resection).\n\n          -  Malabsorption disorders\n\n          -  Lactose intolerance\n\n          -  Significant weight loss during the past three months (more than 5% of initial weight)\n\n          -  Have a regular consumption of medication\n\n          -  Regular supplements (vitamins and minerals) intake during the previous month\n\n          -  Have an alcohol intake: > 2 units a day\n\n          -  Smoker (more than 2 cigarettes a day)\n\n          -  Illicit substances intake, as stated on the medical screening questionnaire\n\n          -  Allergy to any food or medication\n\n          -  Anaemia defined by a number of erythrocytes or hemoglobin Hb or hematocrit Ht which\n             are inferior to laboratory normal ranges\n\n          -  Having given blood in the past  three months or willing to give blood in the 3 months\n             following the completion of the study\n\n          -  Intense physical activity > 3 hours per week\n\n          -  Currently participating or having participated in another clinical trial during the\n             past month.\n\n          -  Volunteer who cannot be expected to comply with the protocol, including consuming\n             rapidly the study products, chronic medication intake"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01727583", 
            "org_study_id": "12.10.MET"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Lipid 1", 
                    "Lipid 2", 
                    "Lipid 3", 
                    "Lipid 4"
                ], 
                "description": "Intake of meals characterized by lipid composition", 
                "intervention_name": "meal intake", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Lipid-free", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Healthy", 
        "lastchanged_date": "November 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lausanne", 
                    "country": "Switzerland", 
                    "zip": "1000"
                }, 
                "name": "Nestl\u00e9 CDU / Metabolic Unit"
            }
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "5", 
        "official_title": "Boosting the Secretion of GLP-2 and GLP-1 Intestinal Hormones by Nutrients", 
        "overall_official": {
            "affiliation": "Nestl\u00e9 / CDU / Metabolic Unit", 
            "last_name": "Maurice Beaumont, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "GLP-2 and GLP-1 are measured using Elisa", 
            "measure": "GLP-2 and GLP-1 kinetics", 
            "safety_issue": "No", 
            "time_frame": "changes from baseline to 4 hours following meal intake"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01727583"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Those hormones will be measured based on enzymatic technics", 
            "measure": "Intestinal and metabolic hormones", 
            "safety_issue": "No", 
            "time_frame": "Changes from baseline to 4 hours following meal intake"
        }, 
        "source": "Nestl\u00e9", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nestl\u00e9", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}